Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02823405 |
| Title | Neoadjuvant X4P-001 and Pembrolizumab in Patients With Resectable Melanoma (X4P-001-MELA) |
| Acronym | X4P-001-MELA |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | X4 Pharmaceuticals |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Clinical Site | Atlanta | Georgia | 30322 | United States | Details | |
| Clinical Site | Iowa City | Iowa | 52242 | United States | Details | |
| Clinical Site | Houston | Texas | 77030 | United States | Details | |
| Clinical Site | Salt Lake City | Utah | 84112 | United States | Details |